07 May | 2021
Dra. Eider Arenaza-Urquijo has been elected Vice President of an ISTAART Area of professional interest
The researcher of the Clinical Research Group, Biomarkers and Risk Factors of the BBRC will vice-chair the group "Reserve, Resilience and Protective Factors of the International Society to advance research and treatment of Alzheimer’s
Dra. Eider Arenaza-Urquijo, member of the Clinical Research, Biomarkers and Risk Factors group of the BarcelonaBeta Brain Research Center (BBRC) has been appointed vice president of the 'Reserve, Resilience and Protective Factors' group of the International Society to advance research and development of Alzheimer's treatment (ISTAART). The researcher, who currently holds the position of communications chair on the group's Executive Committee, has been elected number two in this professional area of interest (PIA), created by the Alzheimer's Association.
Dra. Arenaza-Urquijo has been part of the ‘Reserve, Resilience and Protective Factors’ group since 2015, where she had previously served as Program President. The group's Executive Committee is responsible for overseeing the area's operations, providing and sharing developments in the scientific field in which it operates, coordinating scientific and educational activities, and representing the area on the ISTAART Advisory Board.
The goals of the international group are to establish a network and collaborative forum to drive knowledge and research into mechanisms that can promote reserve and resilience, and to help prevent or delay cognitive aging and Alzheimer's disease; develop consensus guidelines on research criteria to study cognitive reserve and resilience, propose strategies to investigate different underlying brain mechanisms (neuroprotective or compensatory); and promote collaborative projects in this field.
ISTAART is a professional society of the American Alzheimer's Association (Alzheimer's Association), which includes scientists, doctors and other professionals active in the field of research to understand the causes and be able to offer treatments against the disease and other dementias. All this, with a clear mission: to increase the progress ratio of Alzheimer's research and dementia.
